Cargando…
T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621516/ http://dx.doi.org/10.1097/01.HS9.0000890960.29449.17 |
_version_ | 1784821574672580608 |
---|---|
author | Sureda-Balari, Anna Terol, M. José Domingo-Domènech, Eva Rodriguez, Ana Pilar González Mohedo, Francisca Hernández Céspedes, Javier Núñez De La Cruz Vicente, Fátima Muñoz, Carmen Martínez Díaz, M. Elena Amutio Córdoba, Raul Izquierdo, Antonia Rodríguez Domínguez, Samuel Romero Meijide, Javier Briones Greil, Richard Velázquez, Miriam Moreno Rubio, Araceli Oteiro, Mariana Bastos Gómez, Pilar Avivi, Irit Casanova, María Del Campo García, Raquel Noriega, Victor Blanco, José Javier Sánchez Sanz, Ramón. García |
author_facet | Sureda-Balari, Anna Terol, M. José Domingo-Domènech, Eva Rodriguez, Ana Pilar González Mohedo, Francisca Hernández Céspedes, Javier Núñez De La Cruz Vicente, Fátima Muñoz, Carmen Martínez Díaz, M. Elena Amutio Córdoba, Raul Izquierdo, Antonia Rodríguez Domínguez, Samuel Romero Meijide, Javier Briones Greil, Richard Velázquez, Miriam Moreno Rubio, Araceli Oteiro, Mariana Bastos Gómez, Pilar Avivi, Irit Casanova, María Del Campo García, Raquel Noriega, Victor Blanco, José Javier Sánchez Sanz, Ramón. García |
author_sort | Sureda-Balari, Anna |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-9621516 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-96215162022-11-01 T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial. Sureda-Balari, Anna Terol, M. José Domingo-Domènech, Eva Rodriguez, Ana Pilar González Mohedo, Francisca Hernández Céspedes, Javier Núñez De La Cruz Vicente, Fátima Muñoz, Carmen Martínez Díaz, M. Elena Amutio Córdoba, Raul Izquierdo, Antonia Rodríguez Domínguez, Samuel Romero Meijide, Javier Briones Greil, Richard Velázquez, Miriam Moreno Rubio, Araceli Oteiro, Mariana Bastos Gómez, Pilar Avivi, Irit Casanova, María Del Campo García, Raquel Noriega, Victor Blanco, José Javier Sánchez Sanz, Ramón. García Hemasphere Relapsed/Refractory Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621516/ http://dx.doi.org/10.1097/01.HS9.0000890960.29449.17 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
spellingShingle | Relapsed/Refractory Sureda-Balari, Anna Terol, M. José Domingo-Domènech, Eva Rodriguez, Ana Pilar González Mohedo, Francisca Hernández Céspedes, Javier Núñez De La Cruz Vicente, Fátima Muñoz, Carmen Martínez Díaz, M. Elena Amutio Córdoba, Raul Izquierdo, Antonia Rodríguez Domínguez, Samuel Romero Meijide, Javier Briones Greil, Richard Velázquez, Miriam Moreno Rubio, Araceli Oteiro, Mariana Bastos Gómez, Pilar Avivi, Irit Casanova, María Del Campo García, Raquel Noriega, Victor Blanco, José Javier Sánchez Sanz, Ramón. García T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial. |
title | T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial. |
title_full | T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial. |
title_fullStr | T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial. |
title_full_unstemmed | T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial. |
title_short | T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial. |
title_sort | t098: brentuximab vedotin plus eshap (breshap) versus eshap in patients with relapsed or refractory classical hodgkin’s lymphoma. interim results of the breselibet prospective clinical trial. |
topic | Relapsed/Refractory |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621516/ http://dx.doi.org/10.1097/01.HS9.0000890960.29449.17 |
work_keys_str_mv | AT suredabalarianna t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT terolmjose t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT domingodomenecheva t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT rodriguezanapilargonzalez t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT mohedofranciscahernandez t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT cespedesjaviernunez t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT delacruzvicentefatima t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT munozcarmenmartinez t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT diazmelenaamutio t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT cordobaraul t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT izquierdoantoniarodriguez t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT dominguezsamuelromero t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT meijidejavierbriones t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT greilrichard t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT velazquezmiriammoreno t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT rubioaraceli t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT oteiromarianabastos t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT gomezpilar t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT aviviirit t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT casanovamaria t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT delcampogarciaraquel t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT noriegavictor t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT blancojosejaviersanchez t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial AT sanzramongarcia t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial |